PTGS2 and type 2 diabetes mellitus: In patients with OA and type II diabetes mellitus, the combined administration of a COX-2 inhibitor and metformin resulted in a reduced incidence of joint replacement compared with patients receiving a COX-2 inhibitor alone during a 10-year period of follow-up [72].